CLL Topics Banner: Therapies, Research and Patient Education for Chronic Lymphocytic Leukemia
CLL Topics Home Navigation Topics Alert Learning Tools About Us Feedback Feedback
Full Menu

Clinical Trials

  • el
  • pt
  • mystery molecule

    Mitoxantrone plus FCR — British Version

    Date: August 18, 2024

    by Chaya Venkat

    A Comparison of the U. K. and M. D. Anderson Protocols

    Related Articles:
    Mitoxantrone plus FCR;
    More on Mitoxantrone plus FCR.

    monarch Leeds Hospital

    Several readers have written to us in the last few days, requesting a comparison of the FCR+M clinical trial at M. D. Anderson (see our review of this trial at Mitoxantrone to Turbocharge FCR Combo? and More on Mitoxantrone plus FCR) with the trial announced earlier the U.K., using the same four drug combination. Don’t let the alphabet soup get to you, FCR+M is the same as FCM+R. To recap, the four drugs are fludarabine (F), cyclophosphamide (C), Rituxan (R) and mitoxantrone (M).

    Since we have reviewed the rationale for this drug combination in our earlier articles, we will not cover that ground again. In this update we will describe the design of the U. K. trial, with a few comments on how it seems to differ from the M. D. Anderson approach. Drs. Peter Hillmen and Andy Rawstron are both involved in this U.K. trial. Our information is based on Patient Information Sheet dated October 2024. Please bring it to our attention if there are later versions of this information sheet, especially if the later versions differ substantially from the details below.

    The U.K. Trial Design

     

     

    ———

    Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.


    Copyright Notice:

    Copyright © 2024-2007 CLL Topics, Inc. All Rights Reserved.

    All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.

    However, you may download and print material from CLLTopics.org exclusively for your personal, noncommercial use.

    ———

    MDACC

     

    GuideCompass
    up arrow